Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants
- Status
- RECRUITING
- Phase
- PHASE1
Clinical Trials Related to SKYRIZI
Related studies linked through entity extraction aliases.
Exploring the Effects of IL-23 Inhibition by Risankizumab on Psoriasis Autoimmunity
- Status
- UNKNOWN
- Phase
- PHASE4